COMPUGROUP MED.SE O.N.
COMPUGROUP MED.SE O.N.
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: COP
ISIN: DE0005437305

DGAP-Adhoc: CompuGroup Medical SE: Management Board of CompuGroup Medical SE decides share buyback

  • 64

DGAP-Ad-hoc: CompuGroup Medical SE / Key word(s): Share Buyback
CompuGroup Medical SE: Management Board of CompuGroup Medical SE decides share buyback

13-Dec-2018 / 17:12 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Key word(s): Share Buyback

Management Board of CompuGroup Medical SE decides share buyback

Koblenz, December 13, 2018 - The Management Board of CompuGroup Medical SE, Koblenz, ISIN DE0005437305 (the "Company"), has decided today to make use of the authorization pursuant to Sec. 71 para. 1 no. 8 of the German Stock Corporation Act (Aktiengesetz, "AktG") to repurchase shares of the Company, which was granted by the general meeting of May 20, 2015.

In aggregate, up to 500,000 shares of the Company shall be repurchased, corresponding to a portion of the current nominal share capital of approximately 0.94%, subject to an overall purchase volume limit of EUR 20,000,000.00 (excluding ancillary costs of purchase). The repurchased shares may be used for all purposes covered by the authorization.

The shares will be acquired through the stock exchange. The share buyback will be carried out by a credit institute. The share buyback will be conducted pursuant to the Safe-Harbour-Rules of Article 5 of the Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 (Market Abuse Regulation), in conjunction with the Delegated Regulation (EU) 2016/1052 of the Commission of March 8, 2016. The credit institute will decide independently when to repurchase the shares and, on each occasion, how many shares to acquire, without the Company having any influence over these decisions.

The share buyback will be carried out in the time period from December 17,2018 until April 30, 2019. The purchase price per share to be paid by the Company must not exceed, or fall short of, the non-weighted average stock exchange price of the Company's shares, as determined by the closing auction in Xetra trading at the Frankfurt Stock Exchange on the last five trading days before the day of purchase, by more than 10%.

Further details will be published separately by the Company prior to the start of the share buyback. The Management Board reserves the right to terminate the share buyback prematurely at any time.

All transactions will be published weekly following their consummation on the website of the Company (www.cgm.com) in the Investor Relations section.

For further information, please refer to:

CompuGroup Medical SE
Investor Relations
Maria Trost 21
56070 Koblenz, Germany
T: 49 (0) 261 8000-6200
F: 49 (0) 261 8000-3200
Contact person: Christian B. Teig, Chief Financial Officer


13-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)261 8000 6200
Fax: +49 (0)261 8000 3200
E-mail: [email protected]
Internet: www.cgm.com
ISIN: DE0005437305
WKN: 543730
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

758031  13-Dec-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=758031&application_name=news&site_id=centralchart
EQS Group
EQS Group

EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.